(R) -CMPD-39

• Description :

  (R) -CMPD-39 is the R enantiomer of CMPD-39 (HY-141659) . CMPD-39 is a selective non-covalent inhibitor of the ubiquitin-specific protease USP30 (IC50 =~20 nM), with high selectivity over other DUB family members (1-100 μM) . CMPD-39 inhibits the deubiquitinating activity of USP30, enhances the ubiquitination of mitochondrial proteins TOMM20 and SYNJ2BP; thus, CMPD-39 promotes phosphoubuitin accumulation, thereby accelerating mitochondrial autophagy (mitophagy) and peroxisomal autophagy (pexophagy) . CMPD-39 significantly restores impaired mitochondrial function in dopaminergic neurons derived from Parkinson's disease patients[1][2].

• UNSPSC :

  12352005

• Target :

  Deubiquitinase; Mitophagy

• Related Pathways :

  Autophagy; Cell Cycle/DNA Damage

• Applications :

  Neuroscience-Neurodegeneration

• Field of Research :

  Neurological Disease

• Purity :

  99.78

• Solubility :

  DMSO : 100 mg/mL (ultrasonic)

• Smiles :

  CC(C)(C)NS(=O)(C1=CC=C(C=C1)NC([C@H](NC(C2=CC=C(C=C2)F)=O)CC3=CC=CC=C3)=O)=O

• Molecular Formula :

  C26H28FN3O4S

• Molecular Weight :

  497.58

• References & Citations :

  [1]Kluge AF, et al. Novel highly selective inhibitors of ubiquitin specific protease 30 (USP30) accelerate mitophagy. Bioorg Med Chem Lett. 2018 Aug 15;28 (15) :2655-2659. |[2]Rusilowicz-Jones EV, et al. Benchmarking a highly selective USP30 inhibitor for enhancement of mitophagy and pexophagy. Life Sci Alliance. 2021 Nov 29;5 (2) :e202101287.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported